FOXP3 and breast cancer: Taken together, these results not only confirmed that the DNA-binding FKH domain of FOXP3 is required for binding Gal-1, but also suggested that the DNA-binding ability of FOXP3 might be abolished by its interaction with Gal-1 in the breast cancer cells.